THDBH120 vs VK2735
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
THDBH120
Developed by Tonghua Dongbao Pharmaceutical
NCT06951945 · Phase 1 · completed
The trial was randomized, double-blind, and placebo-controlled, which is a sound design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s) (78 days): Phase Ib multiple-dose, randomized, double-blind, placebo-controlled study: THDBH120 led to weight loss of up to 9.36% at six weeks. The two lower-dosed regimens led to weight loss of 7.38% after four weeks and 8.03% after six. Three dosing regimens that involved increasing doses every two or four weeks all showed significance against placebo. (not_applicable)
Result source: NCT06951945
VK2735
Developed by Viking Therapeutics
NCT06828055 · Phase 2 · completed
This randomized, triple-blind, placebo-controlled Phase 2 trial (n=280) in adults with obesity found that oral VK2735 produced significantly greater weight loss than placebo at 13 weeks, up to 12.2% versus 1.3% (placebo-adjusted 10.9%, p<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2027 · NCT07838740 (registry estimate)
Reported efficacy
Percent (relative) change from baseline in body weight after 13 weeks of treatment: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 (met)
Result source: NCT06828055
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | THDBH120 | VK2735 |
|---|---|---|
| Body weight, % change | —Not reported | —Trial running · NCT07104500 |
| Weight loss of 5% or more | —Not reported | —Trial running · NCT07104500 |
| Weight loss of 10% or more | —Not reported | —Trial running · NCT07104500 |
| Waist circumference, change (cm) | —Not reported | —Trial running · NCT07104500 |
Body weight, % change
- THDBH120
- —Not reported
- VK2735
- —Trial running · NCT07104500
Weight loss of 5% or more
- THDBH120
- —Not reported
- VK2735
- —Trial running · NCT07104500
Weight loss of 10% or more
- THDBH120
- —Not reported
- VK2735
- —Trial running · NCT07104500
Waist circumference, change (cm)
- THDBH120
- —Not reported
- VK2735
- —Trial running · NCT07104500
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
THDBH120: no structured comparison results are available for Obesity.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: THDBH120's landscape · VK2735's landscape